Liraglutide

Indications:

• Improvement of glycemic control in adults with type 2 diabetes mellitus.
• Treatment of adults with obesity or overweight, having weight-related comorbidities or complications.

Mechanism of Action: Liraglutide mimics the action of the endogenous hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, delays gastric emptying, and reduces appetite and food intake.

Pharmacokinetics:

• Absorption: Subcutaneously administered, with peak plasma concentrations achieved in 11 hours.
• Distribution: Vd approximates 20-25 L.
• Metabolism: Metabolized via endogenous pathways similarly to large proteins without a specific organ as a major route of elimination.
• Excretion: Mainly through feces.

Form: Liraglutide API is typically found as a clear and colorless solution or as a white lyophilized powder.